10x Genomics adds global CROs

By The Science Advisory Board staff writers

January 24, 2022 -- 10x Genomics has expanded its 10x Certified Service Provider network to include three leading clinical research organizations (CROs). The organizations will partner with 10x Genomics to support global biopharmaceutical companies seeking to leverage 10x Genomics' single-cell and spatial technologies to power new therapeutic discoveries and accelerate drug development.

The three organizations selected for the 10x Genomics Program are Q2 Solutions, Azenta Life Sciences, and CellCarta.

Incorporating single-cell and spatial capabilities into large-scale clinical research studies can help biopharmaceutical companies predict resistance to therapies in cancer patients and analyze endpoint molecular readouts in cancer trials. Furthermore, single-cell technology can help researchers understand correlative immunological responses to drug therapies, or examine the molecular mechanisms behind vaccine-elicited cell-mediated immunity, among other applications.

The 10x Genomics CRO Program involves a rigorous evaluation of each applicant's capabilities, comprehensive training, and yearly recertification to ensure designated partners meet and maintain a high standard of performance and service excellence, according to the firm. All three global CRO partners bring their own unique expertise to the program.

Q2 Solutions, an Iqvia company, is a clinical trial laboratory services organization that provides comprehensive testing, project management, supply chain, biorepository, biospecimen, and consent-tracking solutions. Azenta Life Sciences is a provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to get to market faster. CellCarta is a provider of specialized precision medicine laboratory services to the biopharmaceutical industry.

10x Genomics opens Singapore manufacturing facility
10x Genomics has opened a manufacturing and commercial facility in Singapore, expanding its reach into the Asia-Pacific region. The facility is the company's...
10x Genomics reports revenue gains in Q2
10x Genomics reported revenue growth in the second quarter of 2021 of 170% over the same quarter a year ago.
10x Genomics inks license deal with Bio-Rad
10x Genomics and Bio-Rad Laboratories have settled their legal dispute and signed a global settlement and cross-license agreement.
10x Genomics launches low-throughput gene expression kit
10x Genomics has launched its chromium single-cell gene expression low-throughput kit, a new offering designed to enable single cell analysis.

Copyright © 2022 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter